Results - Unaudited Financial Results for the Quarter and Half Year ended September 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts more than Nifty Microcap 250 and 3.3 pts more than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Choksi Asia Ltd reported strong Q2 FY26 results with revenue from operations rising ~58% year-on-year to ₹1,329.23 lacs (vs ₹841.98 lacs in Q2 FY25). For the half year, revenue grew ~56% YoY to ₹2,518.98 lacs. Net profit for Q2 more than doubled to ₹134.65 lacs (vs ₹65.02 lacs), translating to an EPS of ₹2.36 (vs ₹1.14). For H1, PAT grew ~11% to ₹242.08 lacs. The company's balance sheet remains healthy with total equity of ₹3,917.36 lacs and borrowings of only ~₹304 lacs. However, operating cash flow turned negative at ₹(49.65) lacs for the half year due to a sharp rise in trade receivables. The results reflect the merged entity post the Choksi Asia Pvt Ltd amalgamation, with prior period figures restated. Auditor Karia & Shah issued an unmodified limited review report.
Strong top-line and quarterly profit growth are positive signals for shareholders, though the H1 profit growth of ~11% is far more modest than the quarterly surge, and negative operating cash flow driven by rising receivables is a point to watch. Overall, the results are constructive for the stock.